MA54941A - Polythérapie pour le traitement de malignités des cellules b - Google Patents
Polythérapie pour le traitement de malignités des cellules bInfo
- Publication number
- MA54941A MA54941A MA054941A MA54941A MA54941A MA 54941 A MA54941 A MA 54941A MA 054941 A MA054941 A MA 054941A MA 54941 A MA54941 A MA 54941A MA 54941 A MA54941 A MA 54941A
- Authority
- MA
- Morocco
- Prior art keywords
- malignities
- cell
- treatment
- multiple therapy
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806148P | 2019-02-15 | 2019-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54941A true MA54941A (fr) | 2021-12-22 |
Family
ID=69740437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054941A MA54941A (fr) | 2019-02-15 | 2020-02-14 | Polythérapie pour le traitement de malignités des cellules b |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200262925A1 (fr) |
| EP (1) | EP3923945A1 (fr) |
| JP (1) | JP2022520429A (fr) |
| KR (1) | KR20210129111A (fr) |
| CN (1) | CN113766918A (fr) |
| AU (1) | AU2020222359A1 (fr) |
| BR (1) | BR112021015964A2 (fr) |
| CA (1) | CA3129593A1 (fr) |
| EA (1) | EA202192256A1 (fr) |
| IL (1) | IL285458A (fr) |
| JO (1) | JOP20210225A1 (fr) |
| MA (1) | MA54941A (fr) |
| MX (1) | MX2021009821A (fr) |
| PH (1) | PH12021551936A1 (fr) |
| SG (1) | SG11202108770TA (fr) |
| WO (1) | WO2020165861A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191509A1 (ru) * | 2018-11-30 | 2021-10-26 | Янссен Байотек, Инк. | Способы лечения фолликулярной лимфомы |
| WO2025217275A2 (fr) * | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Compositions ciblées sur des cellules immunitaires et procédés associés |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014168975A1 (fr) * | 2013-04-08 | 2014-10-16 | Pharmacyclics, Inc. | Combinaison thérapeutique à base d'ibrutinib |
| MX2016005283A (es) * | 2013-10-25 | 2017-02-20 | Pharmacyclics Llc | Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia. |
| SMT202200285T1 (it) * | 2014-08-11 | 2022-09-14 | Acerta Pharma Bv | Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1 |
| WO2016128912A1 (fr) * | 2015-02-12 | 2016-08-18 | Acerta Pharma B.V. | Combinaisons thérapeutiques d'un inhibiteur de btk, d'un inhibiteur de pi3k, d'un inhibiteur de jak-2, d'un inhibiteur de pd-1, et/ou d'un inhibiteur de pd-l1 |
| EP3383396B1 (fr) * | 2015-12-04 | 2023-07-12 | Alexion Pharmaceuticals, Inc. | Cerdulatinib et venetoclax pour le traitement des lymphoms non hodgkiniens |
| WO2018033135A1 (fr) * | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Utilisation d'une combinaison comprenant un inhibiteur de btk pour le traitement de cancers |
-
2020
- 2020-02-14 US US16/791,217 patent/US20200262925A1/en not_active Abandoned
- 2020-02-14 JP JP2021547345A patent/JP2022520429A/ja active Pending
- 2020-02-14 CA CA3129593A patent/CA3129593A1/fr active Pending
- 2020-02-14 JO JOP/2021/0225A patent/JOP20210225A1/ar unknown
- 2020-02-14 EA EA202192256A patent/EA202192256A1/ru unknown
- 2020-02-14 PH PH1/2021/551936A patent/PH12021551936A1/en unknown
- 2020-02-14 MX MX2021009821A patent/MX2021009821A/es unknown
- 2020-02-14 CN CN202080029634.3A patent/CN113766918A/zh active Pending
- 2020-02-14 KR KR1020217029364A patent/KR20210129111A/ko active Pending
- 2020-02-14 EP EP20708643.0A patent/EP3923945A1/fr not_active Withdrawn
- 2020-02-14 WO PCT/IB2020/051270 patent/WO2020165861A1/fr not_active Ceased
- 2020-02-14 AU AU2020222359A patent/AU2020222359A1/en not_active Abandoned
- 2020-02-14 BR BR112021015964-9A patent/BR112021015964A2/pt not_active Application Discontinuation
- 2020-02-14 SG SG11202108770TA patent/SG11202108770TA/en unknown
- 2020-02-14 MA MA054941A patent/MA54941A/fr unknown
-
2021
- 2021-08-09 IL IL285458A patent/IL285458A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113766918A (zh) | 2021-12-07 |
| BR112021015964A2 (pt) | 2021-10-05 |
| KR20210129111A (ko) | 2021-10-27 |
| JOP20210225A1 (ar) | 2023-01-30 |
| PH12021551936A1 (en) | 2022-05-23 |
| US20200262925A1 (en) | 2020-08-20 |
| MX2021009821A (es) | 2021-11-12 |
| IL285458A (en) | 2021-09-30 |
| EP3923945A1 (fr) | 2021-12-22 |
| EA202192256A1 (ru) | 2021-10-27 |
| JP2022520429A (ja) | 2022-03-30 |
| SG11202108770TA (en) | 2021-09-29 |
| AU2020222359A1 (en) | 2021-09-02 |
| WO2020165861A1 (fr) | 2020-08-20 |
| CA3129593A1 (fr) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3565846A4 (fr) | Agents thérapeutiques protéiques pour le traitement de cellules sénescentes | |
| MA51418A (fr) | Inhibiteurs de glycolate oxydase pour le traitement de maladies | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| EP3302485A4 (fr) | Cerdulatinib pour le traitement des affections malignes à cellules b | |
| EP3661553A4 (fr) | Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes | |
| EP3630196A4 (fr) | Polythérapies pour le traitement de cancers | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| EP3846830A4 (fr) | Méthodes et compositions pour le traitement de maladie musculo-squelettiques | |
| EP3766497A4 (fr) | Médicament pour le traitement de la toux | |
| EP3630080A4 (fr) | Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer | |
| EP3773221A4 (fr) | Traitement pour l'hydrocéphalie | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3316887A4 (fr) | Inhibiteurs de gls1 pour le traitement de maladies | |
| EP3716966A4 (fr) | Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie | |
| EP3413898A4 (fr) | Utilisation de tréhalose pour le traitement de maladies neurologiques | |
| MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| EP3844294A4 (fr) | Thérapie génique non perturbatrice pour le traitement de la galactosémie | |
| IL290880A (en) | Treatment of symptoms induced by the menstrual cycle | |
| ZA201903795B (en) | Treatment of water | |
| MA54941A (fr) | Polythérapie pour le traitement de malignités des cellules b | |
| EP3852744A4 (fr) | Thérapie combinée pour le traitement du mélanome de la choroïde | |
| GB201916428D0 (en) | Treatment of hydro-carbon-contaminated materials | |
| EP3833378A4 (fr) | Traitement des verrues |